Toronto-based Xagenic Inc has closed a syndicated Series A financing for $10 million to develop new technology for rapid diagnostic testing. Funding for the privately held molecular diagnostics firm was provided by CTI Life Sciences, Ontario Emerging Technologies Fund and QIAGEN NV. The financing follows a $2.2-million seed round in 2010 led by MaRS Innovation. The company's testing platform will be used in hospitals, clinics and physicians' offices....